Literature DB >> 18627569

Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.

Marie-Luise Gross1, Eberhard Ritz.   

Abstract

Cardiac disease is the leading cause of death in uremic patients. In contrast to previous opinion, coronary events account for a relatively small proportion of cardiac deaths, the most common causes being sudden death and heart failure. Against this background the current text will discuss noncoronary cardiac pathology, specifically the pathogenesis and the morphological findings caused by (pathological) cardiac hypertrophy, cardiac interstitial fibrosis and microvascular disease.

Entities:  

Mesh:

Year:  2008        PMID: 18627569     DOI: 10.1111/j.1525-139X.2008.00454.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  58 in total

Review 1.  Hemodialysis-induced cardiovascular disease.

Authors:  Shadi Ahmadmehrabi; W H Wilson Tang
Journal:  Semin Dial       Date:  2018-04-06       Impact factor: 3.455

Review 2.  Uremic Toxins - Novel Arrhythmogenic Factor in Chronic Kidney Disease - Related Atrial Fibrillation.

Authors:  Shih-Yu Huang; Yi-Ann Chen; Shih-Ann Chen; Yi-Jen Chen; Yung-Kuo Lin
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

3.  Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism.

Authors:  Darren A Yuen; Kim A Connelly; Andrew Advani; Christine Liao; Michael A Kuliszewski; Judy Trogadis; Kerri Thai; Suzanne L Advani; Yuan Zhang; Darren J Kelly; Howard Leong-Poi; Armand Keating; Philip A Marsden; Duncan J Stewart; Richard E Gilbert
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

4.  Subjective Global Assessment-Dialysis Malnutrition Score and cardiovascular risk in hemodialysis patients: an observational cohort study.

Authors:  Leonardo Spatola; Silvia Finazzi; Albania Calvetta; Francesco Reggiani; Emanuela Morenghi; Silvia Santostasi; Claudio Angelini; Salvatore Badalamenti; Giacomo Mugnai
Journal:  J Nephrol       Date:  2018-06-23       Impact factor: 3.902

5.  Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort.

Authors:  Klara Torlén; Kamyar Kalantar-Zadeh; Miklos Z Molnar; Tania Vashistha; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 8.237

6.  Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD.

Authors:  Rafael Kramann; Johanna Erpenbeck; Rebekka K Schneider; Anna B Röhl; Marc Hein; Vincent M Brandenburg; Merel van Diepen; Friedo Dekker; Nicolaus Marx; Jürgen Floege; Michael Becker; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

Review 7.  Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins.

Authors:  Suree Lekawanvijit; Henry Krum
Journal:  J Physiol       Date:  2014-06-06       Impact factor: 5.182

8.  Renal dysfunction and diastolic impairment among British ethnic minorities with hypertension: the Ethnic-Echocardiographic Heart of England Screening Study.

Authors:  A Shantsila; E Shantsila; P S Gill; G Y H Lip
Journal:  J Hum Hypertens       Date:  2016-09-08       Impact factor: 3.012

9.  Magnetic resonance tissue phase mapping demonstrates altered left ventricular diastolic function in children with chronic kidney disease.

Authors:  Charlotte Gimpel; Bernd A Jung; Sabine Jung; Johannes Brado; Daniel Schwendinger; Barbara Burkhardt; Martin Pohl; Katja E Odening; Julia Geiger; Raoul Arnold
Journal:  Pediatr Radiol       Date:  2016-12-13

10.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.